- Home
- NAVI vs AUPH Comparison
NAVI vs AUPH Comparison
Compare NAVI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- AUPH
- Stock Information
- Founded
- NAVI 1973
- AUPH 1993
- Country
- NAVI United States
- AUPH Canada
- Employees
- NAVI N/A
- AUPH N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- AUPH Health Care
- Exchange
- NAVI Nasdaq
- AUPH Nasdaq
- Market Cap
- NAVI 1.4B
- AUPH 1.1B
- IPO Year
- NAVI N/A
- AUPH 1999
- Fundamental
- Price
- NAVI $15.37
- AUPH $8.86
- Analyst Decision
- NAVI Hold
- AUPH Strong Buy
- Analyst Count
- NAVI 7
- AUPH 2
- Target Price
- NAVI $14.43
- AUPH $11.50
- AVG Volume (30 Days)
- NAVI 873.2K
- AUPH 1.9M
- Earning Date
- NAVI 07-23-2025
- AUPH 07-31-2025
- Dividend Yield
- NAVI 4.17%
- AUPH N/A
- EPS Growth
- NAVI N/A
- AUPH N/A
- EPS
- NAVI 0.52
- AUPH 0.27
- Revenue
- NAVI $699,000,000.00
- AUPH $247,295,000.00
- Revenue This Year
- NAVI N/A
- AUPH $12.15
- Revenue Next Year
- NAVI $0.56
- AUPH $18.31
- P/E Ratio
- NAVI $29.63
- AUPH $33.04
- Revenue Growth
- NAVI N/A
- AUPH 29.20
- 52 Week Low
- NAVI $10.53
- AUPH $5.20
- 52 Week High
- NAVI $16.97
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- NAVI 68.34
- AUPH 64.10
- Support Level
- NAVI $14.87
- AUPH $7.36
- Resistance Level
- NAVI $15.73
- AUPH $9.10
- Average True Range (ATR)
- NAVI 0.48
- AUPH 0.44
- MACD
- NAVI 0.12
- AUPH 0.10
- Stochastic Oscillator
- NAVI 77.84
- AUPH 89.53
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.